Chronic obstructive pulmonary disease (COPD) is a progressive disease of the airways, leading to chronic inflammation of the lung and is the fifth major cause of mortality in the UK. Current treatment options for COPD are limited and do not prevent disease progression. Hence, there is an urgent need for alternative novel therapeutic approaches. Reactive oxygen species play a key role in oxidative stress which is associated with COPD pathogenesis. Hence, oxidative stress is a potential target for new therapies for lung inflammatory disorders. Natural peanut stilbenes such as resveratrol have been shown to exhibit anti-inflammatory properties. In this study, characterisation of a library of stilbene sulfonamide compounds for their impact on cell health and inflammation was carried out in vitro. There was no significant impact observed on cell health at concentrations below 50 μM, indicating their suitability as safe inhaled therapeutic agents. Some of the analogues have shown promising anti-oxidant potential in vitro, displaying similar activity as resveratrol at 10 μM concentrations. These preliminary investigations warrant further investigation of these trans-stilbene sulphonamide analogues as potential new therapeutic candidates for the treatment for human inflammatory lung diseases.